Efficacy and safety of filgotinib for refractory pouchitis in patients with ulcerative colitis

Efficacy and safety of Janus kinase 1 inhibitor for chronic pouchitis in patients with ulcerative colitis - Efficacy of Janus kinase 1 inhibitor for pouchitis

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048070

Enrollment

Registered

2022-07-01

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis, pouchitis

Interventions

Treatment with filgochinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Anti-biotics dependent or refractory pouchitis.

Exclusion criteria

Exclusion criteria: Patients who dose not agree the treatment with filgochinib.

Design outcomes

Primary

Measure	Time frame
imprpvement by using modified pouchitis activity index with treatment.(Evaluations will be performed after 12weeks and 54 weeks of induction.	—

Secondary

Measure	Time frame
Incidence and kinds of adverse events during treatment. Secession from antibiotics use. Alteration of antibiotics dosage.	—

Countries

Japan

Contacts

Public ContactMotoi Uchino

Hyogo medical university Department of Gastroenterological surgery

uchino2s@hyo-med.ac.jp0798456371

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026